Trial Profile
A Pilot Trial to Explore the Link Between Immunological Changes, Efficacy, Safety, and Tolerability of Durvalumab (MEDI4736) Plus Tremelimumab in Chemotherapy-Naïve Men With Metastatic Castration-Resistant Prostate Cancer (CRPC)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 26 May 2022
Price :
$35
*
At a glance
- Drugs Durvalumab (Primary) ; Tremelimumab (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Adverse reactions
- 13 Apr 2021 Status changed from active, no longer recruiting to completed.
- 16 Jul 2020 Planned End Date changed from 30 Jun 2020 to 30 Jun 2021.
- 16 Jul 2020 Planned primary completion date changed from 30 Jun 2019 to 30 Jun 2021.